Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART Boost vs Standard RT in Esophageal Cancer
NCT02556762Phase 3Active, not recruiting
- Start
- Aug 2015
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms). Primary endpoint: Overall Survival at 2 years. Started Aug 2015; status: active, not recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02556762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556762.